Register Login

Ionis Pharmaceuticals Inc (IONS)

Director KLEIN JOSEPH III 🟡 adjusted position in 28.0K shares (2 derivative) of IONIS PHARMACEUTICALS INC (IONS) at $60.00 ($3.0M) Transaction Date: Sep 03, 2025 | Filing ID: 000219

Full text
Register to leave comments
  • News bot Sept. 5, 2025, 12:38 a.m.

    🔍 KLEIN JOSEPH III (Director)

    Company: IONIS PHARMACEUTICALS INC (IONS)

    Report Date: 2025-09-03

    Transaction Summary:

    • Total transactions: 7
    • Derivative instruments: 2
    • Holdings reported: 2
    • Total shares acquired: 28,000
    • Total shares sold: 56,000
    • Total shares held: 16,446

    Detailed Transactions and Holdings:

    • Acquired 16,000 shares of Common Stock (Direct)
      Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 16,000.00 | transaction_form_type: 4
    • Acquired 12,000 shares of Common Stock (Direct)
      Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 28,000.00 | transaction_form_type: 4
    • Sold 28,000 shares of Common Stock at $60.0 per share (Direct)
      Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
    • Holds 0 shares of Common Stock (Direct)
      Date: 2025-09-03 | Code: H | shares_owned_after: 16,346.00
    • Holds 0 shares of Common Stock (Direct)
      Date: 2025-09-03 | Code: H | nature_of_ownership: by Son | shares_owned_after: 100.00 | Footnotes: F2
    • Sold 12,000 shares of Non-Qualified Stock Option (right to buy) at $42.88 per share (Derivative)
      Date: 2025-09-03 | Code: M | Expires: 2028-07-01 | Exercise: 2019-07-02 | equity_swap_involved: 0 | transaction_form_type: 4
    • Sold 16,000 shares of Non-Qualified Stock Option (right to buy) at $52.22 per share (Derivative)
      Date: 2025-09-03 | Code: M | Expires: 2027-07-02 | Exercise: 2018-07-03 | equity_swap_involved: 0 | transaction_form_type: 4

    Footnotes:

    • F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024
    • F2: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Search

News categories